Biosimilars

Regulators and manufacturers are readying for the opening of the US market, but legal wrangles continue to block the way.

We speak to Professor Begoña Calvo to find out more about her research into pharmaco vigilance for biosimilars.

The first US biosimilar has been pocketed and the game is on. We bring six experts to the table to discuss the impact on industry dynamics.

We catch up with Carol Lynch, Global Head of Biopharmaceuticals & Oncology Injectables at Sandoz.

Biologic medicines present unique challenges for pharmacovigilance. And with biosimilars hitting the market, life just got more complicated.

The launch of the world’s first biosimilar monoclonal antibody was a big step forward from a regulatory and scientific standpoint.

Sitting Down With… Nick Haggar, Head of Western Europe, Middle East & Africa, Sandoz, and President of the European Generic Medicines Association (EGA).

Lilly and Sanofi go head-to-head on a diabetes drug. Meanwhile, Hospira sues the FDA over a new generic approval.